Metformin with Everolimus and Octreotide in Pancreatic Neuroendocrine Tumor Patients with Diabetes
Sara Pusceddu(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Buzzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Claudio Vernieri(FIRC Institute of Molecular Oncology), Laura Concas(Fondazione IRCCS Istituto Nazionale dei Tumori), Sara Marceglia(Politecnico di Milano), Luca Giacomelli(University of Genoa), Massimo Milione(Fondazione IRCCS Istituto Nazionale dei Tumori), Livia Leuzzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniela Femia(Fondazione IRCCS Istituto Nazionale dei Tumori), Barbara Formisano(Fondazione IRCCS Istituto Nazionale dei Tumori), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 38
Abstract
A bidirectional relationship seems to exist between diabetes mellitus and development of pancreatic tumors. Metformin, the most widely used drug in the treatment of Type 2 diabetes mellitus, has recently emerged as a potentially active agent in cancer chemoprevention and treatment. In this article, we discuss the potential correlation between glycemic status, administration of antiglycemic treatments, such as metformin or insulin, and prognosis of pancreatic neuroendocrine tumors patients treated with everolimus and octreotide, on the basis of existing evidence and our experience.
Related Papers
No related papers found
Powered by citation graph analysis